Canada markets closed

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
26.60-0.20 (-0.75%)
At close: 08:00AM CEST
Currency in EUR

Valuation Measures4

Market Cap (intraday) 1.22B
Enterprise Value 1.05B
Trailing P/E 8.45
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)8.19
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -9.53

Trading Information

Stock Price History

Beta (5Y Monthly) 0.56
52-Week Change 331.68%
S&P500 52-Week Change 3-16.88%
52 Week High 330.20
52 Week Low 37.40
50-Day Moving Average 314.53
200-Day Moving Average 313.39

Share Statistics

Avg Vol (3 month) 332
Avg Vol (10 day) 3192
Shares Outstanding 546.42M
Implied Shares Outstanding 6N/A
Float 826.62M
% Held by Insiders 111.89%
% Held by Institutions 184.01%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2021
Most Recent Quarter (mrq)Jun 30, 2022


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-32.58%
Return on Equity (ttm)-59.80%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -110.39M
Net Income Avi to Common (ttm)-110.19M
Diluted EPS (ttm)-3.05
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)180.72M
Total Cash Per Share (mrq)4.81
Total Debt (mrq)10.82M
Total Debt/Equity (mrq)7.29
Current Ratio (mrq)6.90
Book Value Per Share (mrq)3.95

Cash Flow Statement

Operating Cash Flow (ttm)-83.69M
Levered Free Cash Flow (ttm)-43.32M